pralsetinib   Click here for help

GtoPdb Ligand ID: 10033

Synonyms: BLU-667 | BLU667 | Gavreto®
Approved drug
pralsetinib is an approved drug (FDA (2020), EMA (2021))
Compound class: Synthetic organic
Comment: Pralsetinib (BLU-667) is a second-generation selective RET kinase inhibitor that is being developed by Blueprint Medicines [2]. It is Compound 130 in patent US20170121312A1 and our structure was drawn from the image therein [1]. Selective RET inhibitors have oncology potential for the treatment of solid tumours with oncogenic RET alterations (e.g. constitutively activating RET point mutations and RET gene rearrangements). They are expected to offer more effective anti-tumour efficacy in RET-driven tumours than the currently available multi-kinase inhibitors (such as cabozantinib and vandetanib) that have limited anti-RET activity, and which have exhibited poor therapeutic responses in this defined patient group.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 135.01
Molecular weight 533.27
XLogP 3.29
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COC1(CCC(CC1)c1nc(C)cc(n1)Nc1n[nH]c(c1)C)C(=O)NC(c1ccc(nc1)n1ncc(c1)F)C
Isomeric SMILES CO[C@@]1(CC[C@@H](CC1)c1nc(C)cc(n1)Nc1n[nH]c(c1)C)C(=O)N[C@H](c1ccc(nc1)n1ncc(c1)F)C
InChI InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19-,27+/m0/s1
InChI Key GBLBJPZSROAGMF-RWYJCYHVSA-N
No information available.
Summary of Clinical Use Click here for help
Pralsetinib (BLU-667) has advanced to clinical evaluation as a treatment for RET-altered solid tumours. Click here to link to ClinicalTrials.gov's full list of BLU-667 studies, including the Phase 3 study (AcceleRET) in patients with RET fusion-positive metastatic non-small cell lung cancer (NSCLC). Based on positive outcomes identified by independent review of top-line data from the Phase 1/2 ARROW clinical trial (NCT03037385), Blueprint Medicines submitted a New Drug Application (NDA) to the FDA in January 2020, for pralsetinib to be considered for regulatory approval for RET fusion-positive NSCLC. A second NDA for pralsetinib for the treatment of patients with medullary thyroid cancer (who have received previous treatment with an approved multi-kinase inhibitor) followed later in 2020. In September 2020, FDA accelarated approval was granted for patients with RET-mutant NSCLCs (based on results from the ARROW trial, and approval for use in certain RET-mutant medullary thyroid cancers and RET fusion-positive thyroid cancers followed in December 2020. Full (regular) FDA approval for RET-mutant NSCLC was issued in August 2023.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03037385 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2 Interventional Blueprint Medicines Corporation